Clinical trials, though limited in scale, have reported reduced fasting insulin and homeostatic model assessment for insulin resistance (HOMA-IR) indices following flavonoid supplementation in PCOS women [83]. The gene discussed is INS; the disease is polycystic ovary syndrome.